RE:RE:Everyday we are getting closer and closer to approval With FDA EUA, I'm pretty confident it clears $0.50. That would say with 239m shares (not including the 76m warrants and options) but 239m shares the company with the only COVID19 Rapid Antigen Saliva Test with CE and FDA EUA is only valued at $120m cad... when just 3 of the big guys (Abbott, Diasorin & Quidel) sold over $5b COVID 19 tests in their last Quarter.
reminder: 30 rapid test makers with FDA EUA, 50 test variations. 16 of the manufacturers have 19 total at home test variations. All nasal. FDA IS PLATNUM IN THE WORLD, and this FDA EUA domino falling on a unobtrusive, self collecting (so POC staff have added protection) Covid19 rapid antigen saliva test will roll in more regulatory approvals quickly from around the world of 7B people.
I believe this company, at FDA EUA only, will be at a minimum of $250m value... closer to $1, simply based on volume of revenues generated by these 30 test makers today on a global perspective. Sales will take it further.
Of course this is my opinion and projection based on market and new BA2 ramp around the world, including US & Canada.